Table 1.
Key characteristics of participants.
| Control subjects | CIS | RRMS | PMS | CIS, RRMS, and PMS | |
|---|---|---|---|---|---|
| N | 17 | 27 | 303 | 40 | 370 |
| EDSS | 27 | 303 | 40 | 370 | |
| 9HPeg and 25FWalk | 14 | 214 | 17 | 245 | |
| MuSIC | 13 | 195 | 8 | 216 | |
|
Females (%) |
11 (65%) |
14 (52%) |
209 (69%) |
22 (55%) |
245 (66%) |
|
Age in years |
28.6 ± 6.1 28.5 [20.8–43.3] |
35.4 ± 9.9 35.4 [20.1–55.4] |
35.0 ± 9.1 34.8 [18.0–59.5] |
47.7 ± 6.9 47.9 [31.5–59.6] |
36.4 ± 9.8 35.9 [18.0–59.6] |
|
Disease duration in years |
0.4 ± 0.8 0.08 [0.02–3.3] |
2.8 ± 4.5 0.5 [0.0–19.6] |
8.3 ± 5.8 6.4 [1.0–19.9] |
3.2 ± 4.9 0.6 [0.0–19.9] |
|
| Patients with at least one SC lesion N (%) |
0 (0%) |
6 (22%) |
230 (76%) |
36 (90%) |
272 (74%) |
| EDSS | n.d. |
1.2 ± 1.0 1.0 [0.0–3.5] |
1.6 ± 1.4 1.5 [0.0–8.5] |
5.1 ± 1.8 5.2 [1.5–9.0] |
1.9 ± 1.8 1.5 [0.0–9.0] |
| 9HPeg | n.d. |
17.8 ± 2.6 16.9 [14.2–23.6] |
19.0 ± 4.4 18.2 [13.5–54.5] |
24.2 ± 7.5 22.8 [17.0–49.8] |
19.3 ± 4.8 18.2 [13.5–54.5] |
| 25FWalk | n.d. |
3.9 ± 0.7 4.1 [2.7–5.1] |
4.4 ± 1.1 4.2 [2.5–14.0] |
9.3 ± 7.1 6.9 [3.6–29.8] |
4.7 ± 2.5 4.2 [2.5–29.8] |
|
Cognition (MuSIC) |
n.d. |
25.8 ± 4.1 26.0 [14–30] |
25.7 ± 4.0 26.0 [10–30] |
19.8 ± 3.7 20.0 [15–26] |
25.5 ± 4.1 26.0 [10–30] |
|
Fatigue (MuSIC) |
n.d. |
6.0 ± 3.5 4.0 [3–13] |
7.9 ± 4.5 7.0 [3–21] |
11.9 ± 4.6 12.5 [3–17] |
7.9 ± 4.5 7.0 [3–21] |
|
Disease modifying drugs None/DMF/FTY/ Glat/INF/Mitox/ NTZ/RTX/Sin |
/ |
26/0/0 0/1/0 0/0/0 |
244/4/6 16/27/0 6/0/0 |
31/1/0 1/3/1 1/1/1 |
301/5/6 17/31/1 7/1/1 |
|
Scanner Achieva/Ingenia/ Verio |
13/2 2 |
14/2 11 |
191/16 96 |
29/2 9 |
234/20 116 |
Values are given in mean ± standard deviation and in median [range].
9HPeg, Nine-Hole Peg Test; 25FWalk, 25-Foot Walk Test; CIS, clinically isolated syndrome; DMF, Dimethyl fumarate; EDSS, Expanded Disability Status Scale; FTY, Fingolimod; Glat, Glatiramer acetate; INF, Interferon ß; Mitox, Mitoxantrone; MuSIC, Multiple Sclerosis Inventory Cognition; n.d., not determined; NTZ, Natalizumab; PMS, progressive multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; RTX, Rituximab; SC, spinal cord; Sin, steroids in intervals, i.e. pulsed methylprednisolone therapy.